© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
April 13, 2022
The decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.
December 24, 2021
All patients achieved a complete response at 3 months.
December 23, 2021
Patients treated with liso-cel had a probability of continued response at 2-years of 49.5%.
November 08, 2021
Yazeed Sawalha, MD, hematologist, Ohio State University Comprehensive Cancer Center, discussed how socioeconomic factors can affect use of ASCT in mantle cell lymphoma.
July 26, 2021
Heterogeneity in the cellular and molecular features of CAR T-cell products contributes to variation in efficacy and toxicity follow treatment with axicabtagene ciloleucel.
June 21, 2021
C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in multiple myeloma.
June 20, 2021
James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.
May 13, 2021
UCARTCS1A is the first allogeneic CAR T-cell product developed to target CS1 and SLAMF7, both of which are highly and consistently expressed in multiple myeloma.
April 22, 2021
Nilanjan Ghosh MD, PhD, highlights progress made with CAR T-cell therapies in B-cell lymphoma and some ongoing trials generating interest in the field.
March 09, 2021
Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies in the space, as well as in follicular lymphoma, and the challenges with using a 5-drug regimen.